"What does it actually cost to run your own pharmacy?" is the question that decides whether a UK telehealth brand stays partnered or starts building. Most founders evaluate it on a back-of-envelope basis — superintendent salary plus premises plus stock. The real answer is denser and more expensive, especially once the hidden costs of both options surface.
This piece is the cost-breakdown side of the build-vs-partner decision. It walks through the line items, identifies the costs founders typically miss, and runs break-even analyses at four monthly-order bands so you can locate yourself on the curve. (For the strategic framework that wraps these economics, see our build-vs-partner decision matrix.)
Capital cost: GPhC fit-out, equipment, software, licensing
The upfront cost of standing up a GPhC-registered pharmacy in the UK is non-trivial.
Premises fit-out. Commercial premises with sufficient floor area for dispensing, secure CD storage, refrigeration, packing area. Lease costs vary by region — £30k–£80k annual lease for a 1,500–2,500 sqft facility outside central London. Fit-out (work surfaces, security infrastructure, refrigerated storage, CCTV, signage) lands £50k–£150k.
Equipment. Dispensing automation (carousel systems, robot pickers — optional but margin-enhancing at scale), refrigerated cabinets, sealing equipment, label printers, scanning infrastructure. £40k–£100k for a solid setup.
Software. Pharmacy management software, dispatch management, EMR integrations. £15k–£40k initial, plus ongoing licensing.
Licensing. GPhC premises fee is currently around £365 per year per registered pharmacy. The fee itself is small; the regulatory preparation isn't. Budget £20k–£40k for legal, consultancy and registration-process labour.
Initial stock. Stock investment to cover demand for 4–6 weeks at projected volume. Highly category-dependent. £30k–£200k+ depending on what you dispense.
Total capital range: £200k–£600k for a competent year-one build. The lower end requires meaningful operational expertise to execute; the higher end builds in resilience.
Operating cost: superintendent salary, dispensing staff, premises, insurance
Operating costs at steady state are where the long-term economics live.
Superintendent pharmacist. Superintendent pharmacist salaries in the UK range £55k–£95k depending on responsibility scope. Smaller operations: lower end. Multi-site or complex specials operations: higher end. This role is statutory; you can't avoid it.
Dispensing staff. Pharmacy technicians (£26k–£38k each), pharmacy assistants (£21k–£28k each), packing staff. Headcount depends on volume — a 5,000-order-per-month operation typically needs 3–5 FTE on the dispensing floor.
Premises. Lease, utilities, business rates, security monitoring. £40k–£100k annually depending on size and location.
Insurance. Insurance costs (professional indemnity plus pharmacy liability) average £8k–£25k annually depending on volume. Higher volumes attract higher premiums; specialist categories (CDs, compounded specials) push to the upper end.
Software and tooling. Ongoing licensing for pharmacy management, dispatch, EMR integrations. £8k–£25k annually.
Stock working capital. Working capital tied up in stock holding, plus inventory wastage. 5–10% of revenue at typical mix.
Total operating cost: £200k–£500k annually for a 5,000-order-per-month operation, scaling roughly sub-linearly with volume.
White-label cost: monthly platform fees, per-order economics, margin share
Partnered economics look very different.
Margin share. The most common UK structure: the platform takes 15–35% of medication revenue. At £150 average order value, a 25% share equals £37.50 per order. For a 5,000-order month, that's £187,500 monthly platform cost — but no fixed pharmacy cost.
Flat monthly fee. Predictable structure: £2k–£20k+ monthly platform fee plus per-order dispensing fee (£3–£12 per order). For a 5,000-order month at £6 per order plus £8k flat fee: £38k monthly total. The numbers look very different from margin share — which is why pricing model matters as much as headline cost.
Hybrid. Small monthly fee plus per-order dispensing fee. Often the most honest pricing structure because it separates platform from dispensing. (Our pricing page shows what hybrid pricing looks like in practice, and our brand model page shows what scope sits inside that pricing.)
The right model depends on volume curve and capital position. Margin-share models work well below 5,000 monthly orders because you don't pay if you don't sell. Above 10,000, flat or hybrid structures usually win because per-order economics dominate.
The line items founders model are roughly 40% of the actual total cost. The hidden costs — locum cover, regulatory remediation, software migrations, stock obsolescence, founder time — are the other 60%. Build the model with all of it before deciding.
Hidden costs of in-house — locum cover, holiday cover, regulatory remediation
The line items above are what founders model. The hidden costs are what they miss.
Locum and holiday cover. Your superintendent pharmacist takes leave. So does your dispensing team. Locum cover for a pharmacist runs £30–£45 per hour with daily minimums. A pharmacy that operates 6 days per week with 4 weeks of pharmacist leave annually plus illness cover lands £15k–£30k unplanned annually.
Regulatory remediation. A GPhC inspection finding requires written remediation, often within tight timelines. Consultancy and legal support to respond costs £5k–£25k per significant finding. Most pharmacies have at least one minor finding in any three-year window.
Software migrations. Your pharmacy management software vendor changes their pricing. Or sunsets a product. Or you outgrow it. Migration cost: £20k–£80k including data migration, retraining, parallel running.
MHRA Specials licensing. If you compound, MHRA Specials manufacturer licensing requires separate inspection and ongoing GMP compliance. Annual cost: £25k–£60k including the dedicated facility area, batch-level documentation, and QA oversight.
Stock obsolescence and recalls. Stock that expires before being dispensed becomes a write-off. Stock subject to a manufacturer recall becomes a refund-and-replace headache. Budget 2–4% of revenue for this.
Founder time. Hardest to price, but real. A founder running a pharmacy operation is not a founder running the brand. Most operators underprice this until twelve months in.
Hidden costs of white-label — dilution risk, switching cost, vendor concentration
Partnering has its own hidden costs.
Brand dilution risk. If your platform supports many brands and one of them has a regulatory finding, your operational uptime is exposed even if you didn't cause the issue. Diligence the partner's portfolio for risk concentration.
Switching cost. Moving from one partner to another is expensive. Patient data migration, in-flight order handling, prescriber re-onboarding, contract negotiation. Budget £40k–£150k for a meaningful switch — and six to twelve months of operational distraction.
Vendor concentration. Single-vendor dependency means a vendor outage, regulatory finding or commercial dispute stops your business. Some brands mitigate with secondary partners; most don't.
Innovation lag. Your roadmap is constrained by the partner's. If they don't support a new product category, you can't launch it.
Break-even analysis at 1k, 5k, 10k and 25k monthly orders
Worked numbers — illustrative; your specific category and AOV will shift them.
1,000 monthly orders, £150 AOV = £150k monthly revenue.
- Partnered (25% margin share): £37.5k monthly. £450k annually.
- In-house: £35k–£50k monthly operating cost (if you can keep it that low at this volume — barely). £400k–£600k annually plus the £300k–£500k capital amortised. Net: in-house loses on cash and capital at this scale.
- Verdict: partner.
5,000 monthly orders, £150 AOV = £750k monthly revenue.
- Partnered: £187.5k monthly. £2.25m annually.
- In-house: £35k–£50k monthly operating cost = £420k–£600k annually + capital amortisation. Roughly £600k–£800k all-in annually.
- Verdict: in-house wins on pure economics — but only if you can execute. Most brands at this volume still partner because operational risk and founder bandwidth tilt the calculus.
10,000 monthly orders, £150 AOV = £1.5m monthly revenue.
- Partnered: £375k monthly. £4.5m annually.
- In-house: £60k–£90k monthly operating cost (scaled team). £720k–£1.08m annually all-in.
- Verdict: in-house wins decisively on economics. Most brands at this volume have built or are actively building.
25,000 monthly orders, £150 AOV = £3.75m monthly revenue.
- Partnered: £937k monthly. £11.25m annually.
- In-house: £100k–£140k monthly operating cost. £1.2m–£1.68m annually all-in.
- Verdict: in-house is the only sensible answer. The build-versus-partner question is settled; the only remaining question is execution speed.
The arithmetic is honest. The hard part is being honest about which volume curve you're actually on — and which hidden costs apply to your specific brand.
The 5,000-order threshold is where the conversation flips from financial to operational. The 10,000-order threshold is where it flips from operational to inevitable.
What to do this week
If you're sitting on this question:
- Calculate your projected twelve-month monthly volume realistically.
- Apply the partnered economics at your AOV and target margin share — that's your "do nothing" cost.
- Apply the in-house economics with conservative assumptions (high end of operating cost, full year-one capital amortised over three years).
- Compare the two on a three-year and five-year horizon. The longer horizon often favours building; the shorter horizon almost always favours partnering.
- Talk to two brands that built in-house at your projected volume and ask what they wish they'd modelled differently.
The arithmetic is honest. The hard part is being honest about which volume curve you're actually on, and which hidden costs apply to your specific brand.
